Status: Recruiting
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Participants needed: 79
Trial details
Phase: Phase 1Age: 18-100Biological sex: AllType: InterventionalSponsor: Marker Therapeutics, Inc.Updated: Aug 20, 2025Locations: 7
Eligibility criteria
All applicable inclusion and
Participant must be ≥ 18 years of age and capable of giving signed informed cons... [+58]